This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Giroux, V. Articles by Iovanna, J. L. Search for Related Content PubMed PubMed Citation Articles by Giroux, V. Articles by Iovanna, J. L.

p8 Is a New Target of Gemcitabine in Pancreatic Cancer Cells

Authors' Affiliation: Institut National de la Sante et de la Recherche Medicale, Unité 624, Stress Cellulaire, Parc Scientifique et Technologique de Luminy, Marseille, France

Requests for reprints: Juan Iovanna, Centre de Recherche INSERM, Unité 624, Stress Cellulaire, Parc Scientifique et Technologique de Luminy, case 915, 13288 Marseille Cedex 9, France. Phone: 33-491827533; Fax: 33-491826083; E-mail: iovanna{at}marseille.inserm.fr.

Gemcitabine is the only available chemotherapeutic treatment of pancreatic cancers. It is, however, moderately effective, showing a tumor response rate of only 12%. The aim of this work was to identify new pathways involved in the resistance of pancreatic cancer cells to gemcitabine, in the hope of developing new adjuvant strategies to enhance its therapeutic efficacy. Comparison of gene expression patterns of five human pancreatic cancer cell lines showing different degrees of resistance to gemcitabine revealed specific overexpression of several genes in the most resistant. One of them encoded the antiapoptotic p8 protein. We found that (a) knocking down p8 expression in gemcitabine-resistant cells promoted cell death and increased caspase-3 activity; (b) forced overexpression of p8 in gemcitabine-sensitive cells increased their resistance to gemcitabine-induced apoptosis; and (c) gemcitabine down-regulated p8 mRNA expression. These results suggest that, in pancreatic cancer cells, a large part of gemcitabine-induced apoptosis results from the inhibition of the constitutive antiapoptotic activity of p8. Hence, targeting the p8-associated pathway could be a new adjuvant therapy improving the response of patients with pancreatic cancer to gemcitabine treatment.

This article has been cited by other articles:

				L. Li, B. Fridley, K. Kalari, G. Jenkins, A. Batzler, S. Safgren, M. Hildebrandt, M. Ames, D. Schaid, and L. Wang Gemcitabine and Cytosine Arabinoside Cytotoxicity: Association with Lymphoblastoid Cell Expression Cancer Res., September 1, 2008; 68(17): 7050 - 7058. [Abstract] [Full Text] [PDF]

				V. Giroux, J. Iovanna, and J.-C. Dagorn Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance FASEB J, October 1, 2006; 20(12): 1982 - 1991. [Abstract] [Full Text] [PDF]